IL17A and psoriasis: The 0.05% desoximetasone treatment—which is a moderate-potency steroid, typically used for children [20]—demonstrated a similar potential to inhibit the protein expression of the IL-23/IL-17/TNF-α axis in psoriasis-like skin when loaded into the designed formulation compared with high- to super-potency steroids, including Esperson and clobetasol [20].